Evidence map›Paper›PMID 42044176›Full record

ArticleEuropean journal of public health2026

Early dynamics of multimorbidity in 17.4 million people in Spain: onset patterns and prognostic value.

Ignatios Ioakeim-Skoufa, Jorge Vicente-Romero, Francisca González-Rubio, Mercedes Aza-Pascual-Salcedo, Clara Laguna-Berna, Ermengol Sempere-Verdú, Caterina Vicens-Caldentey, Vicente Palop-Larrea, María Pilar Arroyo-Aniés, Óscar Esteban-Jiménez and 7 more

Abstract read
In one paragraph

Article in European journal of public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Ignatios Ioakeim-SkoufaFaculty of Medicine and Health Sciences, Universitat de Barcelona (UB), Barcelona, Spain.ORCID 0000-0002-6518-749X
Jorge Vicente-RomeroDepartment of Pharmacology, Physiology and Legal and Forensic Medicine, Faculty of Medicine, University of Zaragoza, Zaragoza, Spain.ORCID 0000-0003-4629-6743
Francisca González-RubioEpiChron Research Group on Chronic Diseases, Aragon Health Sciences Institute (IACS), Aragon Health Research Institute (IIS Aragón), Miguel Servet University Hospital, Zaragoza, Spain.ORCID 0000-0001-5939-4436
Mercedes Aza-Pascual-SalcedoEpiChron Research Group on Chronic Diseases, Aragon Health Sciences Institute (IACS), Aragon Health Research Institute (IIS Aragón), Miguel Servet University Hospital, Zaragoza, Spain.ORCID 0000-0002-8937-5559
Clara Laguna-BernaEpiChron Research Group on Chronic Diseases, Aragon Health Sciences Institute (IACS), Aragon Health Research Institute (IIS Aragón), Miguel Servet University Hospital, Zaragoza, Spain.ORCID 0009-0007-2903-8159
Ermengol Sempere-VerdúSpanish Society of Family and Community Medicine (semFYC), Drug Utilisation Work Group, Barcelona, Spain.ORCID 0000-0002-1665-0732
Caterina Vicens-CaldenteySpanish Society of Family and Community Medicine (semFYC), Drug Utilisation Work Group, Barcelona, Spain.ORCID 0000-0002-9387-625X
Vicente Palop-LarreaSpanish Society of Family and Community Medicine (semFYC), Drug Utilisation Work Group, Barcelona, Spain.ORCID 0000-0002-1804-0436
María Pilar Arroyo-AniésSpanish Society of Family and Community Medicine (semFYC), Drug Utilisation Work Group, Barcelona, Spain.
Óscar Esteban-JiménezSpanish Society of Family and Community Medicine (semFYC), Drug Utilisation Work Group, Barcelona, Spain.
Ramón Orueta-SánchezSpanish Society of Family and Community Medicine (semFYC), Drug Utilisation Work Group, Barcelona, Spain.
Isabel Barrio-DíezSpanish Society of Family and Community Medicine (semFYC), Drug Utilisation Work Group, Barcelona, Spain.
Pilar Marín-MurilloSpanish Society of Family and Community Medicine (semFYC), Drug Utilisation Work Group, Barcelona, Spain.
Sallie-Anne PearsonMedicines Intelligence Research Program, School of Population Health, University of New South Wales, Sydney, Australia.ORCID 0000-0001-7137-6855
Carmen Gómez-VaqueroRheumatology Department, Hospital Universitari de Bellvitge, Barcelona, Spain.ORCID 0000-0001-6425-0349
Antonio Gimeno-MiguelEpiChron Research Group on Chronic Diseases, Aragon Health Sciences Institute (IACS), Aragon Health Research Institute (IIS Aragón), Miguel Servet University Hospital, Zaragoza, Spain.ORCID 0000-0002-5440-1710
Miguel Ángel Hernández-RodríguezSpanish Society of Family and Community Medicine (semFYC), Drug Utilisation Work Group, Barcelona, Spain.ORCID 0000-0001-7545-8057

Funding

Carlos III Institute of Health, Ministry of Science and InnovationEuropean Union and European Union's NextGenerationEU fundsGobierno de AragónResearch Network on Chronicity, Primary Care, and Health Promotion RD21/0016/0019Research Network on Chronicity, Primary Care, and Health Promotion RD24/0005/0013
6 · The paper itself

Abstract

Multimorbidity, the coexistence of two or more chronic diseases, has become a defining challenge for ageing societies. Yet evidence on when and how chronic diseases begin to cluster, and on the prognostic importance of this timing, remains limited. We used nationwide primary care electronic health records covering 17.4 million people in Spain to reconstruct the onset and progression of chronic disease over the life course. The first recorded diagnosis was used to trace temporal trajectories of multimorbidity by age and sex. We examined how the first condition, age at diagnosis, and time since that diagnosis were associated with advanced (≥3 diseases), multisystem (≥2 organ systems), and complex multimorbidity (≥3 organ systems), as well as premature mortality (<50 and <65 years) and outcomes related to polypharmacy and high-risk prescribing, using multivariable regression and gradient boosting models. By 2021, more than one in three Spaniards lived with a chronic condition, and over half of adults aged 45 years or older had multimorbidity. Among them, nearly 60% had complex multimorbidity. The time elapsed since the first diagnosis showed the closest link to further accumulation, followed by age at first diagnosis and current age. Later onset, particularly after the mid-50s, was associated with faster decline once disease emerged. The timing of the first chronic condition is a powerful but often overlooked prognostic marker. Public health strategies delaying onset and integrating early management could substantially reduce the long-term burden of multimorbidity in European populations.

Indexed as

MultimorbidityAdolescentAdultAgedAged, 80 and overAge of OnsetChronic DiseaseElectronic Health RecordsFemaleHumansMaleMiddle AgedPrimary Health CarePrognosisSpainYoung Adult

Identifiers

PMID42044176
PMCPMC13117620

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.